Subject(s)
Biomarkers/blood , Peripheral Nervous System Diseases/diagnosis , Vascular Endothelial Growth Factor A/blood , Vasculitis/diagnosis , Diagnosis, Differential , Humans , Peripheral Nervous System Diseases/drug therapy , Sensitivity and Specificity , Steroids/therapeutic use , Treatment Outcome , Vasculitis/drug therapyABSTRACT
The authors report an unusual family with hereditary spastic paraplegia (HSP) with frontal lobe dysfunction having the onset in the sixth decade. All the patients showed hypoperfusion in the frontal lobes and thalami on SPECT. Neuropathologic findings revealed thin corpus callosum and degeneration in the thalamic dorsomedial nuclei as well as degeneration of the corticospinal tracts. This family was likely affected by a novel form of HSP characterized by frontal lobe dysfunction caused by thalamic degeneration.
Subject(s)
Dementia/etiology , Frontal Lobe/pathology , Spastic Paraplegia, Hereditary/pathology , Thalamus/pathology , Adult , Age of Onset , Aged , Atrophy , Dementia/pathology , Disease Progression , Fatal Outcome , Female , Frontal Lobe/diagnostic imaging , Frontal Lobe/physiopathology , Gliosis/etiology , Humans , Magnetic Resonance Imaging , Memory Disorders/etiology , Memory Disorders/pathology , Middle Aged , Mood Disorders/etiology , Mood Disorders/pathology , Pyramidal Tracts/pathology , Severity of Illness Index , Spastic Paraplegia, Hereditary/complications , Spastic Paraplegia, Hereditary/diagnostic imaging , Spastic Paraplegia, Hereditary/physiopathology , Thalamus/diagnostic imaging , Tomography, Emission-Computed, Single-PhotonABSTRACT
BACKGROUND: Cysteinyl leukotrienes have been shown to be important in the pathogenesis of allergen-induced (atopic) asthma and rhinitis. Skin manifestations of atopic dermatitis have been reported to improve with leukotriene antagonists. Montelukast, a newer leukotriene antagonist, which is efficacious and safe in patients with asthma 6 years of age and older, has not been reported as therapy for atopic dermatitis. This article reports findings from a pilot study designed to determine whether montelukast is effective in decreasing the signs or symptoms of atopic dermatitis. OBJECTIVE: Our purpose was to compare the efficacy of montelukast with placebo as a treatment for patients with atopic dermatitis. METHODS: The study involved 8 adult patients (male and female) with at least 1 year of intermittent or persistent atopic dermatitis as determined by Hanifin criteria. Medication was given in a randomized, double-blind, placebo-controlled, crossover manner over 8 weeks as adjunctive treatment. Global evaluation of 6 signs (erythema, induration, excoriation, lichenification, scaling, erosion) were scored on a 0 to 3 scale each week, with a blinded investigator evaluating at the initiation, crossover, and final visit. A 30% decrease in total score was considered clinically significant. RESULTS: A significant difference in atopic dermatitis scores between placebo and active agent (P =.014) was recognized. There was no significant interaction between order and treatment. Atopic dermatitis scores tended to be higher with placebo. The mean standard deviation was 8.7 +/- 2.0. The mean for active agent was 6. 8 +/- 2.1. CONCLUSION: This study demonstrates that there is a modest, but significant, alleviation of atopic dermatitis with the use of the leukotriene antagonist montelukast used in an adjunctive manner over a 4-week period.
Subject(s)
Acetates/therapeutic use , Dermatitis, Atopic/drug therapy , Leukotriene Antagonists/therapeutic use , Quinolines/therapeutic use , Adolescent , Adult , Cyclopropanes , Double-Blind Method , Female , Humans , Male , Pilot Projects , Sulfides , Treatment OutcomeSubject(s)
Breast Neoplasms , Lymphoma, Large-Cell, Anaplastic/diagnosis , Neoplasms, Second Primary/diagnosis , Skin Neoplasms/diagnosis , Arm , Diagnosis, Differential , Female , Humans , Lymphoma, Large-Cell, Anaplastic/pathology , Middle Aged , Neoplasms, Second Primary/pathology , Skin Neoplasms/pathologyABSTRACT
Fixed drug eruptions due to Tylenol (paracetamol, acetaminophen) are very rare. The authors report two additional cases and review the literature.
